- Home
- TTRX vs AARD Comparison
TTRX vs AARD Comparison
Compare TTRX & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$4.09
HOLD
Current Price
$11.93
Company Overview
Basic Information| Metric | TTRX | AARD |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.8M | 231.9M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | TTRX | AARD |
|---|---|---|
| Price | $4.09 | $11.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $30.63 |
| AVG Volume (30 Days) | 95.2K | ★ 167.6K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $4.88 |
| 52 Week High | $26.50 | $19.58 |
Technical Indicators
Market Signals| Indicator | TTRX | AARD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 59.31 |
| Support Level | N/A | $9.18 |
| Resistance Level | N/A | $10.44 |
| Average True Range (ATR) | 0.00 | 0.87 |
| MACD | 0.00 | 0.19 |
| Stochastic Oscillator | 0.00 | 94.88 |
Price Performance
Historical Comparison TTRX
AARD
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.